As extensive data on the CALR fragment (amino acids 135–164) termed vasostatin and also, intact CALR, show inhibition of angiogenesis via suppression of endothelial cell proliferation and VEGF levels, the action of CALR in the posterior portion of the eye for the treatment of macular degeneration, currently treated with anti‐VEGF Mabs, which have complications, should be investigated.45, 46, 47. This evidence concerns the gene CALR and macular degeneration.